Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

69 results
Display

Assessment of Anti-tumor Efficacy of Osimertinib in Non-Small Cell Lung Cancer Patients by Liquid Biopsy Using Bronchoalveolar Lavage Fluid, Plasma, or Pleural Effusion

Kim YJ, Ji WJ, Lee JC, Chun SM, Choi CM

Purpose This study was to evaluate anti-tumor efficacy of osimertinib in patients positive for acquired epidermal growth factor receptor (EGFR) T790M mutation in liquid biopsy using plasma, bronchoalveolar lavage fluid (BALF)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Phase I/IIa Randomized Trial Evaluating the Safety and Efficacy of SNK01 Plus Pembrolizumab in Patients with Stage IV Non-Small Cell Lung Cancer

Kim EJ, Cho YH, Kim DH, Ko DH, Do EJ, Kim SY, Kim YM, Jung JS, Kang Y, Ji W, Choi MG, Lee JC, Rho JK, Choi CM

Purpose The aim of this study is to evaluate the safety and efficacy of ex vivo activated and expanded natural killer (NK) cell therapy (SNK01) plus pembrolizumab in a randomized...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Value of the Illness-Death Model for Predicting Outcomes in Patients with Non–Small Cell Lung Cancer

Chae KJ, Choi H, Jeong WG, Kim J

Purpose The illness-death model (IDM) is a comprehensive approach to evaluate the relationship between relapse and death. This study aimed to illustrate the value of the IDM for identifying risk...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Integrin αvβ3 Induces HSP90 Inhibitor Resistance via FAK Activation in KRAS-Mutant Non-Small Cell Lung Cancer

Yoon S, Yang H, Ryu HM, Lee E, Jo Y, Seo S, Kim D, Lee CH, Kim W, Jung KH, Park SR, Choi EK, Kim SW, Park KS, Lee DH

Purpose Heat shock protein-90 (HSP90) remains an important cancer target because of its involvement in multiple oncogenic protein pathways and biologic processes. Although many HSP90 inhibitors have been tested in the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Challenges in the Use of Targeted Therapies in Non–Small Cell Lung Cancer

Rivera-Concepcion J, Uprety D, Adjei AA

Precision oncology has fundamentally changed how we diagnose and treat cancer. In recent years, there has been a significant change in the management of patients with oncogene-addicted advanced-stage NSCLC. Increasing...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
miR-4487 Enhances Gefitinib-Mediated Ubiquitination and Autophagic Degradation of EGFR in Non-Small Cell Lung Cancer Cells by Targeting USP37

Kim MS, Kim SH, Yang SH, Kim MS

Purpose With the identification of epidermal growth factor receptor (EGFR) mutations in non–small cell lung cancer (NSCLC) cells, EGFR–tyrosine kinase inhibitors (TKIs) are being used widely as the first-line of treatment...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
TTF1-positive SMARCA4/BRG1 deficient lung adenocarcinoma

Mehta A, Diwan H, Bansal D, Gupta M

SMARCA4/BRG1-deficient lung adenocarcinoma (SD-LUAD) is being recognized as a distinct subtype based on subtle differences in its clinical, morphological, and immunophenotypic attributes compared to other non–small cell lung carcinomas. We...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non–Small Cell Lung Cancer

Lee C, Kim M, Kim DW, Kim TM, Kim S, Im SW, Jeon YK, Keam B, Ku JL, Heo DS

Purpose Epidermal growth factor receptor kinase domain duplication (EGFR-KDD) is a rare and poorly understood oncogenic mutation in non–small cell lung cancer (NSCLC). We aimed to investigate the acquired resistance...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Programmed death-ligand 1 expression and tumor-infiltrating lymphocytes in non-small cell lung cancer: association with clinicopathologic parameters

Garg G, Prasad KT, Singh N, Gupta P, Muthu V, Das A, Bal A

Background: Data on the prevalence of programmed death-ligand 1 (PD-L1) expression and tumor-infiltrating lymphocytes (TILs) in non–small cell lung cancer (NSCLC) and their clinical significance in Indian patients are limited....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Safety and efficacy of 10-fraction hypofractionated radiation therapy for non-small cell lung cancer

Yoo YJ, Kim SS, Song SY, Kim JH, Ahn SD, Lee Sw, Yoon SM, Kim YS, Park Jh, Jung J, Choi EK

Purpose: To investigate the safety and efficacy of hypofractionated radiation therapy (HFRT) in patients with non-small cell lung cancer who are unfit for surgery or stereotactic body radiation therapy (SBRT)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
SMARCA4/BRG1 protein-deficient thoracic tumors dictate re-examination of small biopsy reporting in non–small cell lung cancer

Mehta A, Bansal D, Tripathi R, Jajodia A

Background: SMARCA4/BRG1 protein–deficient lung adenocarcinomas and thoracic sarcoma are recently described entities that lack distinctive histological features, transcription termination factor 1 (TTF1) reactivity, and actionable driver mutations. The current diagnostic...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Salvage proton beam therapy for locoregional recurrence of non-small cell lung cancer

Shin H, Noh JM, Pyo H, Ahn YC, Oh D

Purpose: This study aimed to evaluate the clinical outcomes and toxicities of salvage proton beam therapy (PBT) in patients with locoregional recurrent non-small cell lung cancer (NSCLC). Materials and Methods:...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Active Treatment Improves Overall Survival in Extremely Older Non–Small Cell Lung Cancer Patients: A Multicenter Retrospective Cohort Study

Lee SY, Hong YK, Ji W, Lee JC, Choi CM, Korean Association for Lung Cancer, Korea Central Cancer Registry

Purpose As the aging of society progresses, the proportion of extremely older lung cancer patients has also increased; However, studies of these patients with non–small cell lung cancer are limited. Therefore,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Phase II Trial of Osimertinib as the First-Line Treatment of Non–Small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1

Park CK, Cho HJ, Choi YD, Oh IJ, Kim YC

Purpose Osimertinib is a potent, irreversible third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for both EGFR-activating and T790M resistant mutation. The treatment efficacy of osimertinib was assessed in...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
An Unusual Case of Metastatic Non-Small Cell Lung Cancer Misidentified as Anaplastic Thyroid Cancer

Ko HM, Kim JR

Metastases from other organs to the thyroid are considered to be extremely rare. Among thyroid malignancies, anaplastic thyroid cancer exhibits similar features to a number of other cancers and can...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer

Shin J, Chung JH, Kim SH, Lee KS, Suh KJ, Lee JY, Kim JW, Lee JO, Kim JW, Kim YJ, Lee KW, Kim JH, Bang SM, Lee JS

PURPOSE: Programmed death-1 (PD-1)/PD-1 ligand (PD-L1) axis blockades have revolutionized the treatment of advanced non-small cell lung cancer (NSCLC). We assessed the effect of platinum-based chemotherapy on tumor PD-L1 expression...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib

Kim S, Kim TM, Kim DW, Kim S, Kim M, Ahn YO, Keam B, Heo DS

PURPOSE: Amplified mesenchymal-epithelial transition factor, MET, is a receptor tyrosine kinase (RTK) that has been considered a druggable target in non-small cell lung cancer (NSCLC). Although multiple MET tyrosine kinase...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2

Park CK, Cho HJ, Choi YD, Oh IJ, Kim YC

PURPOSE: Administering the best treatment after failure of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy requires knowledge of resistance status. In this trial, treatment efficacy of osimertinib...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Salvage Concurrent Chemo-radiation Therapy for Loco-regional Recurrence Following Curative Surgery of Non-small Cell Lung Cancer

Lee KH, Ahn YC, Pyo H, Noh JM, Park SG, Kim TG, Lee E, Nam H, Lee H, Sun JM, Ahn JS, Ahn MJ, Park K

PURPOSE: This study is to report clinical outcomes of salvage concurrent chemo-radiation therapy (CCRT) in treating patients with loco-regional recurrence (LRR) following initial complete resection of non-small cell lung cancer. MATERIALS...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13

Yoo KH, Lee SJ, Cho J, Lee KH, Park KU, Kim KH, Cho EK, Choi YH, Kim HR, Kim HG, Ahn HJ, Lee HY, Yun HJ, Kang JH, Jeong J, Choi MY, Jung SH, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ

PURPOSE: The optimal cytotoxic regimens have not been established for patients with non-small cell lung cancer (NSCLC) who develop disease progression on first-line epidermal growth factor receptor tyrosine kinase inhibitor...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2023 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr